Treatment resistant depression at a glance with traditional, first line antidepressant treatments, as well as a review of the evidence behind esketamine, psilocybin and pramipexole.
Kverno KS, Mangano E. Treatment-Resistant Depression: Approaches to Treatment. J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11. doi: 10.3928/02793695-20210816-01. Epub 2021 Sep 1. PMID: 34459676. Highlights: Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant […]
Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: Preliminary evidence.
Norbury, A., Rutter, S. B., Collins, A. B., Costi, S., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Glasgow, A. M., Brallier, J., Shin, L. M., Charney, D. S., Murrough, J. W., & Feder, A. (2021). Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: Preliminary evidence. […]
Ketamine as treatment for post-traumatic stress disorder: A Review.
Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post-traumatic stress disorder: A Review. Drugs in Context, 8, 1–7. Highlights: PTSD continues to be a problematic psychiatric condition that can be difficult to treat. SSRIs are the first-line treatment, and they are the only pharmaceutical class approved – their use may […]
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept.
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology, 38(12), 2475–2483. Highlights: Participants receiving ketamine first showed a significant rapid reduction in obsessions during the infusion that persisted until 1 week […]
